Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene mutation found for eye disease that mimics macular degeneration

05.08.2003


University of Michigan Kellogg Eye Center scientists have been studying a family whose members have an eye disease that looks like age-related macular degeneration (AMD), but that has a rarer pattern of inheritance that results in an exceptionally high incidence of the disease among family members in the study.



In the August issue of Investigative Ophthalmology & Visual Science (IOVS), Kellogg scientist Radha Ayyagari, Ph.D., and her collaborators from the U-M and other institutions identify the gene associated with this unusual macular disease. They report on the Tyr141Cys mutation in a gene called RDS.

According to Ayyagari, the marked similarity between AMD and the AMD-like disease will help researchers learn more about the molecular basis of AMD. The findings could have even greater significance because Ayyagari and her colleagues suspect that some individuals with AMD may also harbor the RDS mutation.


AMD is a progressive disease affecting the macula, the area of the retina responsible for central vision that enables us to drive, read, and identify faces. It affects about 1.65 million individuals in this country each year; the first symptoms tend to appear at age 60 or older.

Ayyagari’s group discovered the mutation by studying members of five generations of a large family, known to researchers as SUNY901. The family has a high incidence of a macular disease that resembles AMD, begins at age 50 or older, and has both wet and dry forms, much like AMD.

But in contrast to AMD, it has an autosomal dominant mode of inheritance, which means that the disease can be passed to a child by either parent and that the child of an affected parent has about a 50 percent chance of inheriting the disease.

The family members who are affected by the disease may have symptoms with varying degrees of severity, but the condition frequently results in permanent loss of central vision. Co-author Shahrokh C. Khani, M.D., a U-M-trained ophthalmologist now at State University of New York at Buffalo, examined many members of the SUNY901 family.

"From the clinician’s point of view, the eye disorder in this family looks just like AMD," says Khani. "It is very similar in clinical behavior, age of onset, and response to treatment; it appears be a kind of mirror of AMD."

According to Ayyagari, an assistant research scientist in the Department of Ophthalmology and Visual Sciences at the U-M Medical School, the rate at which the SUNY901 family inherited the mutation is one of the most dramatic findings of the research.

"Although AMD has a strong genetic component, we do not see the strong patterns of inheritance we have observed in members of this family," observes Ayyagari. For example, in the fourth generation, at least 18 of the 23 members inherited the mutation from a carrier or affected parent. The odds of encountering the mutation versus the unaffected gene is closer to three-to-one, rather than the expected one-to-one ratio.

When researchers discovered that the same mutation occurred in a smaller family (BCM-AD033), they realized, after further analysis, that this family and the SUNY901 family must have a common ancestor. Researchers had already studied the genealogy of the larger family and traced its members to a single ancestor who emigrated from Germany to North America. Ayyagari adds that RDS has been screened extensively in populations worldwide; the only two families known to have the rare mutation are the two families described in the paper.

Khani observes that the detailed family history of the SUNY901 family presented genetic researchers with an unusual opportunity.

"When you can study a family with such a well-preserved genealogy, it is easier to get to the root of the disease," he says. "Most families find it difficult to identify members beyond a first cousin. In this family we think we can identify the first family members to have developed the disease, in the late 1700s."

Scientists want to understand how the mutation in RDS interferes with the healthy functioning of the eye. They believe that the mutation disrupts the normal structure and function of the RDS protein. As scientists gain more understanding of these processes, they will be able to develop therapies and treatments that counteract or circumvent the effects of the mutations.

In addition to Khani and Ayyagari, coauthors of the paper are: Athanasios J. Karoukis, Rajesh Ambasudhan and Tracy Burch of Kellogg; Joyce E. Young and Richard Stockton of SUNY Buffalo; Richard Alan Lewis of Baylor College of Medicine; Lori S. Sullivan and Stephen P. Daiger of the University of Texas Health Science Center; and Elias Reichel of the New England Eye Center at Tufts University.

Kara Gavin | EurekAlert!
Further information:
http://www.iovs.org
http://www.kellogg.umich.edu

More articles from Life Sciences:

nachricht Biophysicists reveal how optogenetic tool works
29.05.2020 | Moscow Institute of Physics and Technology

nachricht Mapping immune cells in brain tumors
29.05.2020 | University of Zurich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Biotechnology: Triggered by light, a novel way to switch on an enzyme

In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".

Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...

Im Focus: New double-contrast technique picks up small tumors on MRI

Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.

researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...

Im Focus: I-call - When microimplants communicate with each other / Innovation driver digitization - "Smart Health“

Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.

When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...

Im Focus: When predictions of theoretical chemists become reality

Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.

Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...

Im Focus: Rolling into the deep

Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.

A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

International Coral Reef Symposium in Bremen Postponed by a Year

06.04.2020 | Event News

 
Latest News

Black nitrogen: Bayreuth researchers discover new high-pressure material and solve a puzzle of the periodic table

29.05.2020 | Materials Sciences

Argonne researchers create active material out of microscopic spinning particles

29.05.2020 | Materials Sciences

Smart windows that self-illuminate on rainy days

29.05.2020 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>